KCM Investment Advisors LLC Acquires 9,594 Shares of Pfizer Inc. (NYSE:PFE)

KCM Investment Advisors LLC lifted its holdings in Pfizer Inc. (NYSE:PFE) by 7.7% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 133,821 shares of the biopharmaceutical company’s stock after purchasing an additional 9,594 shares during the quarter. KCM Investment Advisors LLC’s holdings in Pfizer were worth $3,550,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in PFE. Retirement Wealth Solutions LLC bought a new position in Pfizer in the 4th quarter valued at $26,000. Rialto Wealth Management LLC acquired a new position in shares of Pfizer during the fourth quarter valued at $26,000. Kohmann Bosshard Financial Services LLC bought a new position in Pfizer in the fourth quarter valued at about $28,000. Noble Wealth Management PBC acquired a new stake in Pfizer in the fourth quarter worth about $31,000. Finally, Curio Wealth LLC bought a new stake in Pfizer during the 4th quarter worth about $32,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on PFE shares. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Bank of America reissued a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. Truist Financial decreased their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Finally, UBS Group cut their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $31.92.

Insider Activity at Pfizer

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the firm’s stock in a transaction dated Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 0.06% of the stock is owned by insiders.

Pfizer Stock Down 5.4 %

Pfizer stock opened at $22.99 on Friday. Pfizer Inc. has a twelve month low of $22.95 and a twelve month high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The company has a 50 day moving average of $25.87 and a 200-day moving average of $26.74. The stock has a market capitalization of $130.39 billion, a PE ratio of 16.31, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company’s revenue was up 24.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.10 EPS. On average, equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.